A physician with an MD from the Tulane University School of Medicine in New Orleans, Louisiana, Dr. Robert J. Tomlinson resides in Fayetteville, AR. Dr. Robert J. Tomlinson treats opioid-dependent patients through the Suboxone Recovery Center of Arkansas.
The Suboxone Recovery Center of Arkansas focuses on induction pharmacotherapy using the brand name drug Suboxone, which contains the active ingredients buprenorphine and naloxone. Like the later pharmacotherapy stages of stabilization and maintenance, the initial induction stage of opioid addiction treatment requires the intake of specific pharmaceuticals in specific doses.
Also known as first-line pharmacotherapy, induction pharmacotherapy introduces new drugs into patients' bodies for the first time. This makes the safety standards of induction pharmacotherapy extremely important. Although buprenorphine-naloxone combination drugs such as Suboxone are highly effective during the induction stage, the US Department of Health and Human Services recommend buprenorphine tablets without naloxone over the first two days of induction for individuals who plan to transition to morphine, methadone, or another longer-acting medication during the latter stages of pharmacotherapy.
The Suboxone Recovery Center of Arkansas focuses on induction pharmacotherapy using the brand name drug Suboxone, which contains the active ingredients buprenorphine and naloxone. Like the later pharmacotherapy stages of stabilization and maintenance, the initial induction stage of opioid addiction treatment requires the intake of specific pharmaceuticals in specific doses.
Also known as first-line pharmacotherapy, induction pharmacotherapy introduces new drugs into patients' bodies for the first time. This makes the safety standards of induction pharmacotherapy extremely important. Although buprenorphine-naloxone combination drugs such as Suboxone are highly effective during the induction stage, the US Department of Health and Human Services recommend buprenorphine tablets without naloxone over the first two days of induction for individuals who plan to transition to morphine, methadone, or another longer-acting medication during the latter stages of pharmacotherapy.
